






Global Map: https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html.

Last week, we had almost 137.9 million cases around the world and 2.9 million deaths.

This week, there are 143.3 million cases and we have 3,050,266 deaths around the world.




Last week in the US:

Total cases: 31,158,087 (almost 31.2 million)


As of yesterday

This week:

Total cases: 31,602,676



In the US, you can see that we are averaging almost 66,000 new cases each day according to the 7-day average. That is down from 70,000 from the previous week.




Last week in the US:

Total deaths: 560,576 (over 560,000)


As of yesterday

This week:


Total deaths: 565,613




The 7-day moving average daily death trend in the United States is about 685 deaths per day.




Moving on to KS specific data. For our first Disease Spread metric, which is the daily rate of new cases, the trend line last week was increasing slightly and this week it looks similar, but really pretty flat.



For hospitalizations, the trend last week was increasing and this week it is flat.



And for deaths, last week the trend was decreasing and it is flat this week.



As of yesterday, we had 306,883 cases (which is an increase of 1,563 cases since last week) and 4,961 deaths statewide (that's an increase of 17 deaths since last week).


There were 593 new cases and 6 new deaths reported from Monday 4/19 to Wednesday 4/21.

	Summary data is updated every Wednesday. Active CO	VID-19 Clusters	
Clusters	Cases	Hospitalizations	Deaths
48	2,771	57	25
Clusters	Cases	Hospitalizations	Deaths
Clusters		D-19 Clusters Hospitalizations	Deaths
1,910	38,268	1,876	2,060
38,268 outbreak-relate	ed cases/306,883 cases (2	12.5%)	

Moving on to outbreaks:


As of late Tuesday night, we had 1,910 outbreaks across the state; This week we have 48 active clusters which is up from 44 last week.

Our percentage of outbreak related cases is 12.5%, outbreak-related hospitalizations is about 18.9% and outbreak-related deaths is about 41.5%.



We currently have 2 active clusters in colleges and universities, 2 in corrections, 9 in LTCFs (that's up from 7 last week), 11 in private businesses and 2 in schools.

Don't forget, if you are interested in seeing the list of named locations with 5 or more cases within the last 14 days, you can go to the dashboard.




MMWR article:

The Kentucky Department for Public Health (KDPH) and a local health department investigated a COVID-19 outbreak in a SNF that occurred after all residents and health care personnel (HCP) had been offered vaccination.

Among 83 residents and 116 HCP, 75 (90.4%) and 61 (52.6%), respectively, received 2 vaccine doses. Twenty-six residents and 20 HCP received positive test results for SARS-CoV-2, including 18 residents and four HCP who had received their second vaccine dose >14 days before the outbreak began. An R.1 lineage variant was detected with whole genome sequencing (WGS). Although the R.1 variant has multiple spike protein mutations, vaccinated residents and HCP were 87% less likely to have symptomatic COVID-19 compared with those who were unvaccinated.

The R.1 variant is not currently identified as a CDC variant of concern or interest, it does have several mutations known to increase transmissibility.



MMWR article:

Among 627 persons with SARS-CoV-2 infection across 75 SNFs since vaccination clinics began, 22 SARS-CoV-2 infections were identified among 12 residents and 10 staff members across 15 facilities ≥14 days after receiving their second vaccine dose (i.e., breakthrough infections in fully vaccinated persons). Nearly two thirds (14 of 22; 64%) of persons with breakthrough infections were asymptomatic; two residents were hospitalized because of COVID-19, and one died. No facility-associated secondary transmission occurred.



COVID-19: Updated Travel-Related Quarantine List

	Туре	Effective Date	Where?
Int	International Travel	On or after April 22, 2021	Argentina, Aruba, Bahrain, Croatia, Cyprus, France, Sweden and Turkey
		On or after April 8, 2021	Andorra, Bermuda, Curacao, Poland, Serbia or Uruguay
		On or after March 26, 2021	Hungary
		On or after March 12, 2021	Estonia
		Between March 26, 2021 - April 22, 2021	Jordan
		Between March 12, 2021 – April 22, 2021	State of Palestine
		Between February 26, 2021 – April 22, 2021	San Marino
	Domestic Travel	On or after April 22, 2021	Minnesota
		On or after April 8, 2021	Pennsylvania
		On or after March 26, 2021	Delaware, Michigan or Rhode Island
		On or after March 12, 2021	New Jersey or New York
		Between April 8 – April 22, 2021	Connecticut
		September 10, 2020	Attendance at out-of-state mass gatherings of 500 or more where you do not socially distance (6 feet) and wear a mask.
<u> </u>	Cruises	On or after March 15, 2020	All cruise ships and river cruises

To protect and improve the health and environment of all Kansans

Fortunately Kansas has continued to slightly improve and is still near the bottom of the US list....unfortunately this means more states and countries that are worse off than Kansas. For the US list:

1. Remove: Connecticut

2. Keep: Michigan New Jersey New York Rhode Island Delaware Pennsylvania


3. Add: Minnesota

For the International list:

1. Remove: San Marino Estonia Jordan

2. Keep: Curacao State of Palestine Uruguay Bermuda Andorra Poland Hungary Serbia

3. Add: Turkey Bahrain Cyprus Croatia France Sweden Aruba Argentina






Vaccine Allocations Next Week

- Pfizer Prime 42,120 doses
- Moderna Prime 31,300 doses
- J&J 0 doses

Please consider Moderna and Pfizer as options in all settings- Avoid missed opportunities





Johnson and Johnson Pause

- A virtual emergency meeting will be held to discuss Janssen (Johnson & Johnson) COVID-19 vaccine on April 23, 2021, 10:00 a.m. to 4:00 p.m. CT
- https://www.ustream.tv/channel/VWBXKBR8af4




Johnson and Johnson Pause


- de Beaumont released some new polling data collected by Frank Luntz after the J&J pause was announced. The poll was conducted April 15-16, 2021. Some points of interest:
 - Americans consider the CDC and FDA's decision to pause the Johnson & Johnson vaccine proof that rigorous safety monitoring is working.
 - 40% of Americans are more likely to get vaccinated than they were one month ago.
 - The partisan gap between Republicans and Democrats willingness to get vaccinated seems to be narrowing. Only 16% of all voters disagreed with the statement "The bottom line is COVID-19 vaccines save lives, and Americans should continue to get vaccinated as soon as possible."
 - 61% of Americans agreed that the J&J pause was an isolated situation and generally vaccines are safe.




Johnson and Johnson Pause

- The following messaging would be most assuring about the safety of J&J:
 - Safety monitoring is working and the government is prioritizing the safety of Americans. The safety monitoring system for vaccines identified the issue as soon as it arose, and this was shared with the public transparently, showing a commitment to safety.
 - As of today, fewer than 10 people of the 6.8 million who have gotten the Johnson & Johnson vaccine to date — have reported serious blood clotting side effects.
 - These events are extremely rare. The chance of being struck by lightning is literally twice that of getting a blood clot from the J&J COVID-19 vaccine.
 - The risk of getting a serious blood clot from the J&J COVID-19 vaccine is less than
 of getting a blood clot from birth control medication, from smoking, or for those
 hospitalized with COVID-19.









FDA Approved Tests as of 4/22/21

FDA has currently authorized 315 tests under EUAs:

- 239 molecular tests (excluding Lab Developed Tests)
- 75 antibody tests
- 23 antigen tests, 18 CLIA Waived + 6 At Home Tests

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitrodiagnostics-euas

To protect and improve the health and environment of all Kansans

Several new high complexity tests.

Roche COBAS has now included high complexity –pooling as part of their EUA.

The Yale Saliva Direct method has added serial screening and their EUA summary included option for collection at home, unsupervised.

1 new CLIA Waived Antigen test.

Note that if you use the link on this slide, it takes you to a general page and you then have to go to individual pages from there to see Molecular or Antigen or Serological tests.



Pooling and Serial Testing Amendment for Certain Molecular Diagnostic Tests for SARS-CoV-2

On April 20, 2021, the FDA issued an amendment allowing certain authorized molecular diagnostic SARS-CoV-2 tests to be distributed and used to pool anterior nasal respiratory specimens from asymptomatic individuals as part of a serial testing program after developers submit a complete notification, including meeting required validation data, as set forth in the letter.

This means that tests with EUAs that are amended by this authorization may be used with pooled anterior nasal specimens from individuals without known or suspected COVID-19 when such individuals are tested as part of a testing program that includes testing at regular intervals, at least once per week.

 $\frac{\text{https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2\#amendment}$

To protect and improve the health and environment of all Kansans

Update from FDA to formally approve certain molecular diagnostic tests to be used for pooled specimens from asymptomatic individuals.

This is for High complexity labs and requires the vendor to submit application and data to support the change.

On this page will be an Exhibit that will list these, but nothing has been posted there yet.



COVID Variants and Testing

Variant	Reported Cases in US	Number of States
B.1.1.7	20,915	52
B.1.351	453	36
P.1	497	31

To protect and improve the health and environment of all Kansans

https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html

This is the last update for this page. CDC will no longer update these numbers after April 12.

B.1.1.7

B.1.351

P.1



COVID Variants and Testing

- KHEL has sequenced over 2,600 samples to date.
- We have published over 950 of our sequences to the GISAID international database.
- There are 2,192 Kansas based sequences currently in GISAID



SARS-CoV-2 Viral Mutations Detection with COVID-19 Tests

- Variant Detection is not diagnostic
- Variants are usually a combination of various mutations.
- PCR techniques can detect some aspects of some variants
 - e.g. S-gene dropout
- But PCR alone cannot positively identify a variant, only if a particular mutation is present.



SARS-CoV-2 Viral Mutations Detection with COVID-19 Tests

- But PCR alone cannot positively identify a variant, only if a particular mutation is present.
- Be aware of misleading claims by vendors to "identify variants".
- These PCR mutation identifications can provide "indications" of a potential variant
- Good for screening which samples could be related to variants
- Should not report as having found a variant until whole genome sequencing is performed.

If you are a lab that is running PCR for COVID detection, we are looking for ways to increase our statewide sequencing efforts



KHEL is looking to partner with labs to increase sequencing



Criteria

KHEL is asking labs to send any positive samples

However, KHEL is particularly interested in the following cases if all samples are not available

• Examples: Areas with high transmission (different age groups, geographic locations, severity), cases in areas with a significant increase of cases over a few weeks (not explained by relaxing public health measures), children in areas with increased incidence of pediatric disease, clusters of cases in people aged <60 without underlying conditions, cases in fully-vaccinated people or when reinfection is suspected

Samples with a CT value <30 are preferred, but higher CT values are OK if samples are of interest



Next steps

- To sign up for the program, Contact KHEL_INFO and include Subject Line: ATTENTION SEQUENCING
 - Samples can be submitted through a form or lab online
 - For regular surveillance tell us how many PCR positives you typically have per week and could send
- If there is a known case of reinfection or potential vaccine break through or "S-Deletion", then contact KHEL for sequencing.
- You should not report PCR mutation screening to anyone as an identified variant. Variants are only identified after confirmation whole genome sequencing
 - Send us extract if possible or a second sample in VTM

Please note: CMS has stated so far that sequencing results cannot be reported back to providers but only to Public Health. We will be working with Public Health staff regarding results of sequences but can only provide aggregate data back to any given laboratory



General Thoughts

- Rapid Antigen Kits Available from KDHE at no charge.
- Community Testing Partners for Antigen Tests
- CLIA Certification Questions: KDHE.CLIA2@ks.gov
- Mobile Labs and Collection Vans available.

To protect and improve the health and environment of all Kansans

If you have a need or an idea on using rapid antigen tests for a particular purpose, please let us know and we may be able to supply the kits at no charge. Go through your County EM.


We are looking for partners to ensure that testing is available across the state and there are still some gaps. If you are doing testing or can do antigen testing for public use (no charge to patient) we may have an opportunity to engage you as a community testing partner in order to fill a gap in current service. You would need to be accessible to the public and we can provide supplies but you would either collect specimens for PCR testing or perform an onsite rapid antigen test.

If you need help with certification to use these Waived Tests, then contact our CLIA office.

If you have an idea on how a mobile laboratory or collection event would support your community or situation, please reach out and let us know.



Voices on Vaccinations is a state-wide effort sponsored by the Kansas Leadership Center and the Kansas Department of Health and Environment. We gathered in community meetings with Black, Latino, Native American, and intellectually or developmentally disabled individuals to hear about their perspectives on COVID-19 vaccination. Then we create culturally appropriate messaging resources to enable more effective communication about COVID-19 vaccination. All of these resources can be found on VoicesOnVaccinations.org. We also aim to build awareness of the vaccines by equipping Champions, community members, and public health practitioners to share insights with diverse communities.



The resources on VoicesOnVaccinations.org come from real Kansans; some of the examples can be seen here. In addition to the testimonials shown here, there are also FAQ graphics, infographics, graphics that outline the steps to get the vaccine, radio ads and a sample newspaper ad. All of these are available in both English and Spanish.



In order to build a network of individuals dedicated to building awareness of, and interest in, the COVID-19 vaccines in diverse Kansas communities, you can become a Champion. A champion is committed to sharing resources and information about the COVID-19 vaccines in ways that mobilize individuals in the following communities in Kansas: Black, Latino, Native American, and individuals with intellectual or developmental disabilities. Business owners, church pastors, nonprofit board members are just some examples of who make great Champions. Our goal is to identify 500 Champions in the state. If you are interested in becoming a Champion, you can sign up by giving your name and email address on the VoicesOnVaccinations.org website.



The next webinar from the National Emerging Special Pathogens Training and Education Center (NETEC) will take place Friday, April 30th at noon CST. This webinar's topic is "Overcoming Challenges to Supporting Your Workforce: Let's Talk." This webinar will: identify three sources of stress for healthcare workers; discuss three obstacles to providing psychological support to healthcare workers; distinguish between healthcare worker and leader responsibility for providing psychological support; and summarize key messages leadership can send to the workforce to encourage help-seeking. To register for the webinar, click the link on the screen or visit: https://netec.org/education-and-training/.



The next webinar in the Emory University COVID-19 ECHO Program is taking place right now, but a recording of it will be available soon. This month's webinar is titled "Long Haul COVID: What Providers Need to Know" and aims to improve practitioners' understanding and identification of long haul COVID-19; to utilize case studies to exemplify how practitioners approach and manage long haul COVID-19 in patients; and to empower practitioners to answer patients' questions about long haul COVID-19. A recording of the webinar will be available using the link on this slide or by visiting the Emory University School of Medicine website.





"The COVID-19 Vaccine for Adult Genetics Patients"

Date: Thursday, May 6, 2021


Time: **10am - 11am CST**

Click **HERE** to register

To protect and improve the health and environment of all Kansans

The May ECHO COVID-19 Program webinar will take place Thursday, May 6 and cover "The COVID-19 Vaccine for Adult Genetics Patients." This webinar will aim: to improve understanding of COVID-19 vaccine physiology and reactogenicity among genetics practitioners; to address providers' concerns around recommending the COVID-19 vaccine to adult genetics patients; to utilize case studies to exemplify how practitioners approach and manage the COVID-19 vaccines with their patients; and to empower genetics practitioners to answer patients' questions about the COVID-19 vaccine. TO register, use the link on the screen or visit:

https://med.emory.edu/departments/medicine/divisions/infectious-diseases/serious-communicable-diseases-program/covid-19-resources/echo-upcoming-session.html.



In response to concerns of access barriers some immigrants are facing regarding documentation requests prior to receiving COVID-19 vaccination, and individuals inappropriately being sent bills for COVID-19 vaccine fees, the Health Resources & Services Administration (HRSA) developed two fact sheets to help both patients and providers better understand their rights and responsibilities regarding access to COVID-19 vaccines. One fact sheet (shown here in Spanish) is geared toward patients, and the other (shown in English) is geared toward providers. They also have social media resources that have launched on their social media pages (shown here). Click the various links to access these resources on the HRSA website.

